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ABSTRACT
Background The World Health Organization recommends that women take 400 µg of folate supplementation daily throughout pregnancy.
We examined the relationship between total folate intake from the diet and supplements at the first prenatal visit and haematological indices at
this visit and subsequently.
Methods Women were recruited at their convenience and in addition to clinical and sociodemographic details, detailed questionnaires on
dietary intakes and supplementation consumption were completed under supervision. A full blood count and serum and red blood cell (RBC)
folate levels were taken.
Results Of the 502 women studied, 97.5% had inadequate total dietary folate intake at the first visit, but, 98.2% were taking folic acid (FA)
supplementation. Only 1.8% (n = 9) had anaemia at their first visit (with no case of macrocytosis). Subsequently, 212 women had a further Hb
sample in the third trimester and 8.5% (n = 18) were anaemic and 43.4% (89/205) were anaemic postnatally. There was a relationship
between the development of anaemia postnatally and lower RBC folate levels at the first visit (P = 0.02).
Conclusions In a country where FA food fortification remains voluntary, these findings support the recommendation that women should start
FA supplementation before pregnancy and continue FA after the first trimester.
Keywords anaemia in pregnancy, folic acid supplementation
Introduction
The associations between maternal anaemia and an increase in
maternal and foetal mortality and morbidity are well estab-
lished, particularly in the developing world.1,2 Anaemia is more
likely to develop as pregnancy advances due to increasing feto-
maternal cellular requirements and physiological changes in
folate metabolism. To adjust for haemodilution during preg-
nancy, anaemia may be defined as a haemoglobin <11.0 g/dL
in the first trimester, <10.5 g/dL in the second and third tri-
mesters and <10.0 g/dL postnatally.3,4
The prevalence of anaemia in pregnancy varies widely due
to the variation in maternal dietary intakes of micronutrients
and in the consumption of supplementary vitamins. In preg-
nant women, the prevalence of anaemia was 6.1% in the
USA, 18.7% in Europe and 55.8% in Africa with inadequate
iron intake the commonest cause.5 As iron deficiency may
result in a microcytic anaemia, it is recommended by the
World Health Organization (WHO) that in regions with a
high prevalence of anaemia, all pregnant women should take
60 mg of iron during pregnancy to prevent iron deficiency
anaemia.6
Inadequate folate intake may result in a macrocytic
anaemia but the recommended nutrient intake values during
pregnancy vary widely between countries.7 In 1991–92, two
landmark RCTs demonstrated that folic acid (FA) supplemen-
tation prevents neural tube defects (NTDs). Subsequently,
national recommendations advised women to start FA before
pregnancy and to continue for the first trimester.8 Many coun-
tries also implemented either voluntary or mandatory FA food
fortification policies because periconceptual FA supplementation
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rates were too low.9 Fortification alone, however, is not deemed
to be adequate to achieve the desired levels with the continuing
intake of a supplement considered a more reliable method,
especially in women following a low carbohydrate or gluten
free diet.10
There is a dearth of recent information as to what impact
the implementation of public health measures on supple-
mentation and fortification with FA have had on develop-
ment of a macrocytic anaemia during pregnancy particularly
in well-resourced settings. It is notable that in a review of
national guidelines from 20 European countries the focus
was on FA supplementation in the first trimester to prevent
NTDs but, no recommendations were made for the rest of
pregnancy to prevent other potential adverse pregnancy out-
comes, despite established dietary deficiencies of folate in
adult women.8 WHO advises 400 µg of FA supplementation
to continue throughout pregnancy in response to fetomater-
nal cellular requirements and evidence of dietary deficiency.6
In a recent prospective observational study, we found that
women needed to start FA supplementation before they
became pregnant to achieve RBC folate measurements asso-
ciated with a decreased risk of NTDs.11 In this secondary
analysis we examined the relationship between maternal
intake of both dietary folate and FA supplementation in
early pregnancy with haematological indices both at the first
prenatal visit and as pregnancy advanced.
Materials and methods
We studied women presenting for prenatal care after ultra-
sound confirmation of an ongoing pregnancy <18 weeks
gestation. The exclusion criteria were women aged <18 years
old and women who could not understand English. Women
were recruited conveniently at their first prenatal visit by a
single researcher (SC). Their height and weight were mea-
sured before calculating body mass index (BMI). Clinical
and sociodemographic details were computerized as part of
the standard medical records by a trained midwife using a
barcode system.
The women also completed a detailed questionnaire under
supervision which included questions on the duration of FA
use, multivitamin use and the brand and dosage of supple-
ments. Their total dietary intake was calculated using
Nutritics Version 3.7 (University Edition). The dietary data
were compiled based on an average daily intake for each
food listed in a retrospective four day dietary history which
was completed under supervision. Care was taken to specify
particular food brands due to the varying content with
respect to voluntary FA fortification.12 Dietary folate equiva-
lent was calculated for the dietary and supplemental intakes
where 1 µg of folate from food is equal to 1 µg DFE. For FA
in fortified food or supplements 1 µg of FA is equal to 1.7 µg
DFE, as folate from food is 50% bioavailable compared to
85% bioavailability from supplementation (85/50 = 1.7).13
In addition, a routine full blood count was taken and
blood for other biomarkers including plasma folate, whole
blood folate and RBC folate levels. A microbiological assay
was used to measure maternal folate.14
The hospital laboratory results system was searched for
any further full blood count results taken over the course of
the pregnancy and the gestation at phlebotomy recorded (if
multiple samples were taken, the sample with the highest Hb
value from each trimester was recorded). Delivery informa-
tion was computerized under midwifery supervision imme-
diately after birth before discharge from the delivery suite.
Data was anonymized and coded in SPSS (IBM SPSS
Statistics version 20). Continuous data were assessed for
normality by visual inspection of the histogram and box-plot
and calculation of kurtosis and skewness. Descriptive statis-
tics were used to describe the characteristics of the study
population and where necessary, continuous variables were
recoded into categorical variables for further analysis.
Independent samples t-test was used to assess the difference
between the mean Hb in the third trimester according to
prepregnancy folic use. Linear regression was used to assess
for relationships between prepregnancy folic acid use and
duration of use and RBC folate levels at the first prenatal
visit and Hb at term. Multiple regression was performed to
control for potential confounding factors where necessary.
Tests for statistical significance were performed with signifi-
cance set at the 95% level.
Approval was granted by the Hospital’s Research and
Ethics Committee and written consent was obtained.
Results
The characteristics of the study population are shown in
Table 1. The study population was similar to the overall hos-
pital population as reported in the Annual Clinical Reports.15
The population studied was predominantly of white European
ethnicity (including Irish) (n = 446, 93.0%(415)) and 30 of the
women reported living in Ireland ≤5 years (n = 388, 7.7%).
One-third (n = 456, 30.5%) reported finishing in full time edu-
cation at ≤18 years of age and of the 308 women providing
the relevant information, the rates of relative income pov-
erty and consistent poverty were 23.9% and 4.2%, respect-
ively (Table 1).
Table 2 shows the dietary intakes and vitamin supple-
ments consumption reported by women at their first ante-
natal visit. Despite voluntary food fortification, only 2.5% of
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women had a total dietary folate considered adequate for preg-
nancy. The median total dietary folate intake reported at the
first visit (n = 398) was 235.2 µg (interquartile range: 143.6 µg).
At the time of the first prenatal visit, 98.2% of women were
taking FA supplementation with only 1.0% deficient based on
red blood cell (RBC) folate level and 0.0% deficient based on
serum folate level. However, 34.3% of women had a RBC fol-
ate level below 906 nmol/L (Table 2).
The incidence of anaemia was 1.7% based on a cut-off of
<11.0 g/dL in the 420 women who presented in the first tri-
mester. The incidence of anaemia in the women who
attended for their first visit in the second trimester (n = 82)
was 2.4% based on a cut-off of <10.5 g/dL. There were 18
cases of anaemia (8.5%) in the 212 women who had a full
blood count taken in the third trimester. Postnatally there
were 89 cases of anaemia based on a cut-off of 10.0 g/dL
(representing 43.4% of the women who had a full blood
count postnatally). There were no cases of macrocytic
anaemia identified in any trimester or postnatally (Table 3).
Women who were anaemic in the third trimester and
postnatally had lower rates of preconceptual folic acid use
compared to those who did not have anaemia (third trimes-
ter; FA use in those with anaemia—27.8% versus FA use in
those who were not anaemic—45.6% (not significant) and
postnatally; FA use in those with anaemia—43.8% versus
FA use in those who were not anaemic—50.9% (not signifi-
cant)) (Supplementary Table S1).
Table 1 Characteristics of the study population (n = 502)
Characteristic
Age (years) (mean ± SD) 30.7 ± 5.5
BMI (kg/m2) (mean ± SD) 26.0 ± 5.5
Nulliparous (%) 42.6% (n = 214)
Current smokers (%) 12.9% (n = 65)
Obese (%) 19.3% (n = 97)
Ethnicity (%) (n = 446)
White European including Irish 93.0% (n = 415)
Afro Carribean 1.8% (n = 8)
Asian 1.4% (n = 6)
Other 3.8% (n = 17)
Finished full time education at ≤18 years (n = 456) 30.5% (n = 139)
Relative income povertya (%) n = 308 23.9% (n = 74)
Consistent povertya (%) 4.2% (n = 13)
Lived in Ireland ≤ 5 years (%) n = 388 7.7% (n = 30)
GA at first visit (weeks) (mean ± SD) 12.5 ± 2.4
Preterm deliveryb (before 37.0 weeks) (%) 4.0% (19)
Birth weightb (g) (mean ± SD) 3422.0 ± 573.3
Birth weightb < 2.5 kg (%) 5.2% (26)
Birth weightb > 4.5 kg (%) 1.8% (9)
Caesarean deliverya (%) 28.4% (134.0)
SD, standard deviation; BMI, body mass index; GA, gestational age.
aThese measures were based upon questions from the European Union—
Survey on Income and Living Conditions (EU-SILC) 2011.16
bData on delivery outcomes were confined to 472 women as 30 women
were lost to further follow up and did not deliver in the hospital.
Table 2 Dietary and supplement intakes and laboratory measurements
of the study population
Dietary intakesa
Median total dietary folate intake (µg) (IQ
range)
235.2 µg (IQ range:
143.6)
Median dietary folate equivalent (µg DFE) (IQ
range)
255.1 µg DFE (IQ range:
185.2)
WHO RNI dietary folate equivalent (µg DFE) 600 µg DFE
Meeting dietary folate recommendations (%) 2.5% (n = 10)
Meeting folate recommendations (based on
dietary and supplemental intake) (%)
100.0%
Median dietary vitamin B12 intake 4.0 µg (IQ range: 2.7)
WHO RNI for dietary vitamin B12 2.6 µg
Meeting dietary vitamin B12
recommendations (%)
77.3% (n = 303)
Median dietary iron intake 9.3 mg (IQ range: 4.4)
EFSA PRI for dietary Iron 27–30mg
Meeting dietary iron recommendations (%) 2.0% (n = 8)
Supplement intake
Taking folic acid prepregnancy (%) 42.8% (n = 215)
Taking folic acid at the first antenatal
visit (%)
98.2% (n = 493)
Laboratory measurement (n = 502)
Serum folate (nmol/L) (median, IQ range) 34.6 (IQ range: 18.1)
Deficient based on serum folate level (%)b 1.0% (n = 5)
Red blood cell folate (nmol/L) (mean, SD) 1137.5 (±443.0)
Deficient based on red blood cell folate
levelc
0.0%
Red blood cell folate <906 nmol/L (%)d 34.3% (n = 172)




SD, standard deviation; IQ range, interquartile range; WHO, World Health
Organization; RNI, recommended nutrient intake (per day); EFSA, European
Food Safety Authority; PRI, population reference intake (per day).
aDietary intakes reported are based on analysis of the food diaries which
were complete for 398 women in the study cohort.
bWorld Health Organization cut off for folate deficiency based on serum
folate <6.8 nmol/L.
cWorld Health Organization (WHO) cut off for folate deficiency based on
red blood cell folate <226.5 nmol/L.
dThe reported threshold concentration for red blood cell folate is reported
as 906 nmol/L by Daly et al.17 Above this concentration, the risk of neural
tube defects (NTDs) was reduced to <8 NTDs/10 000 live births.
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There was a positive relationship identified between a higher
haemoglobin postnatally and a higher RBC folate level at the
first prenatal visit. For women with a Hb > 10.0 g/dL (n =
116) postnatally, the mean RBC folate at the first prenatal visit
was 1202.3 (± 444.4) nmol/L compared to a mean RBC folate
of 1060.1 (± 429.1) nmol/L in those with a Hb < 10.0 g/dL
postnatally (P = 0.02) (Supplementary Table S1).
The overall percentage taking FA prepregnancy was
42.8% (Table 2). The use of FA prepregnancy was lower in
those women reporting that they completed full time educa-
tion at ≤18 years of age (P < 0.001) and amongst those
reporting relative income poverty (P < 0.01). There was no
relationship between prepregnancy FA use and ethnicity or
years lived in Ireland. RBC folate at the first prenatal visit
and Hb in the third trimester had a positive relationship
with the prepregnancy use of FA (P < 0.001 and P < 0.005,
respectively). In particular, women who started FA before
pregnancy were more likely to have a higher RBC folate at
the first prenatal visit (B: 390.1, 95% CI: 316.9–463.2, P <
0.001), and a higher Hb in the third trimester (B: 0.487, 95%
CI: 0.171–0.804, P = 0.003).
While women who started FA prepregnancy had the same
mean haemoglobin at the first prenatal visit compared to
those who did not take prepregnancy FA (12.9 ± 0.8 versus
12.9 ± 0.9 g/dL), they had an increase in their mean haemo-
globin in the third trimester (n = 212, 12.3 ± 1.1 versus 11.9 ±
1.2 g/dL, P = 0.003). Multiple regression was performed to
demonstrate the relationship between taking folic acid pre-
pregnancy and a higher haemoglobin in the third trimester.
The relationship between taking FA prepregnancy and Hb
persisted in the third trimester in the first model after con-
trolling for age, BMI, current smoking and parity (B: 0.348,
95% CI: 0.010–0.686, P = 0.04). As BMI and smoking status
did not show a significant relationship with Hb in the third tri-
mester, they were omitted in the second model (B: 0.361, 95%
CI: 0.028–0.694, P = 0.03) (Table 4).
Discussion
Main findings of this study
Even with voluntary folate food fortification, almost all women
studied (97.5%) had a total dietary folate intake below that
recommended by WHO for pregnancy and breastfeeding,18,19
yet, no woman presenting for prenatal care had a macrocytic
anaemia. The absence of macrocytic anaemia may reflect good
compliance with FA supplementation in early pregnancy.
In total, 98.2% were taking FA supplementation at the time
of phlebotomy. However, women who started FA after they
became pregnant had a lower RBC folate at presentation and
were more likely to have a lower Hb in the third trimester. Of
the women who had a FBC postpartum nearly half were
anaemic. This study highlights the potential benefits of women
starting FA before pregnancy and continuing supplementation
throughout pregnancy, even in a developed country, to prevent
maternal anaemia and possibly blood transfusion.
The primary analysis related to this work demonstrated
that the median time of commencement of FA in the group
that took prepregnancy FA (42.8%) was 12 weeks before
pregnancy and in the remaining women, the median dur-
ation of commencement was 5 weeks post the last menstrual
period (coinciding with the time point of a positive pregnancy
test).11 It was possible in this analysis to demonstrate that
those who commenced FA ≥ 4 weeks prepregnancy were
Table 3 Full blood count parameters measured in each trimester and postnatally
First trimestera Second trimestera Third trimestera Postnatally
(n = 420) (n = 82) (n = 212) (n = 205)
Mean gestation at phlebotomy (antenatal—weeks, postnatal—days) (±SD) 11.7 (±1.4) 16.6 (±2.4) 39.2 (±1.2) 1.9 (±1.2)
Mean Haemoglobin (g/dL) (±SD) 12.9 (±0.9) 13.0 (±0.8) 12.1 (±1.2) 10.2 (±1.5)
Mean MCV (fl) (±SD) 88.7 (±4.1) 88.7 (±4.2) 88.7 (±5.8) 87.4 (±5.7)
Anaemicb (%) 1.7% (n = 7) 2.4% (n = 2) 8.5% (n = 18) 43.4% (n = 89)
Microcytic anaemiac (%) 0.2% (n = 1) 0.0% 3.8% (n = 8) 8.8% (n = 18)
Macrocytic anaemiac (%) 0.0% 0.0% 0.0% 0.0%
SD, standard deviation; MCV, mean corpuscular volume.
aCut-offs for gestation; first trimester <14 weeks, second trimester ≥14 weeks, <28 weeks, third trimester ≥28 weeks. Of the 502 patients, 420 were in
their first trimester at the time of phlebotomy and 82 were in their second trimester. 212 of the 502 patients had a sample taken in the third trimester
between 37 and 42 weeks.
bCut off for anaemia in the first trimester; haemoglobin (Hb) <11 g/dL, second and third trimester Hb <10.5 g/dL and postnatal Hb <10.0 g/dL.
cMicrocytic, MCV < 80 fl; macrocytic, MCV >100 fl.
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more likely to achieve the optimal RBC folate level of >906
nmol/L (86.4 versus 53.3%, P < 0.001).
This study has demonstrated a relationship between use
of FA prepregnancy and a higher haemoglobin in the third
trimester and the relationship persisted upon controlling for
maternal age, BMI, smoking status and parity. Theoretically,
a higher haemoglobin in the third trimester should reduce
the need for blood transfusion due to haemorrhage and
should improve maternal well-being postpartum.
In view of the dietary inadequacies of folate, despite vol-
untary food fortification, our findings strengthen the case
for women continuing FA supplementation throughout
pregnancy, as recommended by WHO, especially if they only
started during pregnancy.6
Considering the strengths of the study, the hospital provides
care for women from all socioeconomic groups across the
urban-rural divide. All women had sonographic confirmation
of gestational age at the first prenatal visit. Clinical and sociode-
mographic data were computerized at the first visit, thus min-
imizing recall bias. Maternal weight and height were measured
before calculating BMI, and not self-reported at the first visit.
Information on dietary intake and supplementation use (includ-
ing the dose and brand of each supplement) were collected at
the same visit by a SC. Biomarkers were also measured at the
same visit. The laboratory is validated for the analysis of plas-
ma folate, whole blood folate and RBC folate. Pregnancy out-
comes were computerized immediately after delivery.
What is already known on this topic
In a study in the USA, for the first time, data on the
reported dietary supplement use and folate status among
pregnant women sampled in the National Health and
Nutrition Examination Survey (NHANES) was analysed in
1296 women from 1999 to 2006 after FA food fortification
became mandatory.20 When surveyed about taking FA either
as a single or multivitamin in the previous 30 days, only
55–60% reported they consumed FA in the first trimester,
76–78% in the second and 88% in the third. The majority
were taking 800 µg as a single supplement. The median RBC
folate was 1255 nmol/L in the first trimester and increased
as pregnancy advanced. No information, however, was pre-
sented on maternal haematological indices.
A mandatory food fortification programme in the USA
has been shown to increase serum folate with a correspond-
ing 19% decline in the incidence of NTDs reported conse-
quently.21,22 A Canadian study based on 95 women of
childbearing age demonstrated that mandatory food fortifi-
cation with FA increased the mean folate consumption by
96 µg/day (within the range predicted by the food fortifica-
tion programme; 70–130 µg/day for adults aged ≥ 19 years).
No one within this cohort met the dietary folate equivalent
for FA without supplementation. Only 14% of women
exceeded the optimal RBC folate of 906 nmol/L associated
with a reduced risk of NTDs.17,23
A systematic review of 31 studies involving 17 771
women examined FA supplementation during pregnancy
and pregnancy outcomes.24 The studies were undertaken
30–45 years previously in both developed and developing
countries using differing dosages of supplementation and
differing definitions of anaemia. The review found no
impact on the mother of FA before delivery on anaemia
(eight studies), haemoglobin levels (12 studies), serum folate
levels (eight studies) or RBC folate levels (four studies). FA
Table 4 Multiple regression analysis showing the relationship between taking folic acid prepregnancy and higher haemoglobin in the third trimester
controlled for maternal age, BMI, smoking status and parity
Variable Coefficient (B) SE 95% CI Pa
Model 1
Folic acid prepregnancy 0.348 0.171 0.010–0.686 0.04
Maternal age 0.034 0.017 0.000–0.068 0.05
Maternal BMI 0.005 0.014 −0.022–0.032 0.71
Smoking status −0.117 0.265 −0.640–0.407 0.66
Nulliparas 0.412 0.176 0.075–0.768 0.02
Model 2
Folic acid prepregnancy 0.361 0.169 0.028–0.694 0.03
Maternal age 0.036 0.017 0.002–0.069 0.04
Nulliparas 0.407 0.172 0.067–0.747 0.02
SE, standard error; CI, confidence interval; BMI, body mass index.
aSignificance value set at 95% level.
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supplementation during pregnancy did, however, reduce the
incidence of megaloblastic anaemia by 79% (four studies;
RR = 0.21 95% CI: 0.11–0.038). As many of the studies
were 30–45 years old, they were conducted before wide-
spread supplementation and fortification practices were
introduced.
The authors had intended to carry out a subgroup analysis
based on different durations of FA supplementation but were
unable to do so because not all studies included baseline
haemoglobin levels and furthermore, the duration and timing
of FA supplementation during pregnancy varied. Such infor-
mation was available for our study as well as information on
FA dosage and other supplements consumed.
What this study adds
Detailed dietary analysis in this study has shown that dietary
folate intakes are inadequate for almost all women. Owing
to supplementation, we have shown that serum and RBC
folate are adequate by the first prenatal visit with a positive
correlation between duration of use and these levels. Beyond
the role of folate in preventing NTDs, folate is an integral
vitamin to fetomaternal cellular development throughout preg-
nancy. We believe this study provides evidence that women
should continue supplementation after the first trimester and
postpartum to avoid anaemia and blood transfusion.
Limitations of this study
Limitations of the study include the fact that this study was
undertaken in a country where fortification of food with fol-
ate is voluntary and not mandatory. Also, we do not have
information as to how many women continued either single
supplementation of FA or iron or multivitamins after the
first trimester.
Supplementary data
Supplementary data are available at the Journal of Public
Health online.
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